NVO
Novo’s pipeline just got another mic-drop
Novo Nordisk spent the day doing what every investor secretly wants from a drugmaker: showing off data. The headline act was CagriSema, which hit its primary goal in the Phase 3 REIMAGINE 1-3 trials by lowering HbA1c and cutting body weight in adults with Type 2 diabetes.
That matters because this isn’t just a “we saw a number move” press release. It’s evidence that Novo’s next-wave obesity and diabetes stack may have real staying power. In plain English: if the drug keeps helping people manage blood sugar and lose weight, the market starts treating it less like a science project and more like an actual money machine.
More than one arrow in the quiver
Novo also dropped Phase 2 data on zenagamtide, aka amycretin, and the results were the kind of thing that makes biotech bulls sit up straighter. The drug improved HbA1c across all doses, and higher doses also helped with body-weight reduction. The company said it’s planning a Phase 3 program in adults with Type 2 diabetes in the second half of 2026.
Meanwhile, Novo tossed in a little commercial victory lap: Wegovy tablets 25 mg crossed 3 million prescriptions in just over five months. That’s a very loud signal that demand is still there, even as competition from Eli Lilly keeps the GLP-1 aisle looking like the busiest shelf in the pharmacy.
Why investors should care
The stock was down about 1% in premarket trading, which is the market’s way of saying, “Nice data, now prove it can scale.” But for shareholders, the bigger takeaway is simple:
- Novo is still producing headline-worthy trial results
- its pipeline now has multiple shots on goal
- and real-world prescription momentum suggests the business isn’t running out of steam anytime soon
Big picture: if obesity and diabetes are the marathon, Novo keeps acting like a runner who still has gas in the tank while everyone else is reaching for a sports drink.